NASDAQ:CYCC - Cyclacel Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $17.00
  • Forecasted Upside: 341.56 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$3.85
▲ +0.01 (0.26%)

This chart shows the closing price for CYCC by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Cyclacel Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CYCC and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CYCC

Analyst Price Target is $17.00
▲ +341.56% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Cyclacel Pharmaceuticals in the last 3 months. The average price target is $17.00, with a high forecast of $17.00 and a low forecast of $17.00. The average price target represents a 341.56% upside from the last price of $3.85.

This chart shows the closing price for CYCC for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 2 investment analysts is to buy stock in Cyclacel Pharmaceuticals. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/5/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/3/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/2/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/2/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/31/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/29/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/28/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/27/2021

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/18/2021LADENBURG THALM/SH SHLower Price TargetBuy$18.00 ➝ $17.00High
4/29/2021OppenheimerInitiated CoverageOutperform$17.00High
5/21/2020LADENBURG THALM/SH SHReiterated RatingBuy$18.00High
5/21/2020Roth CapitalReiterated RatingBuy$24.00High
5/19/2020Brookline Capital ManagementInitiated CoverageBuy$22.00High
5/12/2020Roth CapitalReiterated RatingBuyLow
5/23/2019Roth CapitalReiterated RatingBuyLow
5/15/2019HC WainwrightReiterated RatingBuyLow
10/4/2018Roth CapitalSet Price TargetBuy$160.00Low
9/7/2018LADENBURG THALM/SH SHInitiated CoverageBuy ➝ Buy$125.00Medium
9/5/2018Roth CapitalInitiated CoverageBuy$160.00High
8/10/2018HC WainwrightSet Price TargetBuy$140.00Medium
3/29/2018HC WainwrightReiterated RatingBuyHigh
(Data available from 11/27/2016 forward)

News Sentiment Rating

-0.20 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/1/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/31/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/30/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
7/30/2021
  • 0 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
8/29/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
9/28/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/28/2021
  • 0 very positive mentions
  • 5 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
11/27/2021

Current Sentiment

  • 0 very positive mentions
  • 5 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Cyclacel Pharmaceuticals logo
Cyclacel Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It uses cell cycle, transcriptional regulation and DNA damage response biology to develop medicines for cancer and other proliferative diseases. The company builds a biopharmaceutical business, which is focused in hematology and oncology based on a pipeline of novel drug candidates. Its products include CYC065, seliciclib, and sapacitabine. The company was founded by Ronald J. Berenson, David Philip Lane, and David Glover on August 13, 1996 and is headquartered in Berkeley Heights, NJ.
Read More

Today's Range

Now: $3.85
Low: $3.72
High: $3.90

50 Day Range

MA: $5.03
Low: $3.76
High: $5.72

52 Week Range

Now: $3.85
Low: $3.67
High: $11.42

Volume

31,404 shs

Average Volume

277,235 shs

Market Capitalization

$38.40 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.09

Frequently Asked Questions

What sell-side analysts currently cover shares of Cyclacel Pharmaceuticals?

The following Wall Street research analysts have issued stock ratings on Cyclacel Pharmaceuticals in the last year: LADENBURG THALM/SH SH, Oppenheimer Holdings Inc., and Zacks Investment Research.
View the latest analyst ratings for CYCC.

What is the current price target for Cyclacel Pharmaceuticals?

2 Wall Street analysts have set twelve-month price targets for Cyclacel Pharmaceuticals in the last year. Their average twelve-month price target is $17.00, suggesting a possible upside of 341.6%. Oppenheimer Holdings Inc. has the highest price target set, predicting CYCC will reach $17.00 in the next twelve months. Oppenheimer Holdings Inc. has the lowest price target set, forecasting a price of $17.00 for Cyclacel Pharmaceuticals in the next year.
View the latest price targets for CYCC.

What is the current consensus analyst rating for Cyclacel Pharmaceuticals?

Cyclacel Pharmaceuticals currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CYCC will outperform the market and that investors should add to their positions of Cyclacel Pharmaceuticals.
View the latest ratings for CYCC.

What other companies compete with Cyclacel Pharmaceuticals?

How do I contact Cyclacel Pharmaceuticals' investor relations team?

Cyclacel Pharmaceuticals' physical mailing address is 200 CONNELL DRIVE SUITE 1500, BERKELEY HEIGHTS NJ, 07922. The biotechnology company's listed phone number is (908) 517-7330 and its investor relations email address is [email protected] The official website for Cyclacel Pharmaceuticals is www.cyclacel.com.